Edition:
India

Aldeyra Therapeutics Inc (ALDX.OQ)

ALDX.OQ on NASDAQ Stock Exchange Capital Market

6.62USD
14 Aug 2020
Change (% chg)

$-0.12 (-1.78%)
Prev Close
$6.74
Open
$6.71
Day's High
$6.73
Day's Low
$6.50
Volume
182,120
Avg. Vol
249,646
52-wk High
$8.04
52-wk Low
$1.49

Summary

Name Age Since Current Position

Richard Douglas

67 2016 Independent Chairman of the Board

Todd Brady

48 2012 President, Chief Executive Officer, Director

Joshua Reed

47 2018 Chief Financial Officer

James Gow

53 2020 Senior Vice President - Clinical Development

Stephen Machatha

43 2019 Senior Vice President, Technical Operations

David McMullin

45 2019 Chief Commercial Officer

Ben Bronstein

70 2010 Independent Director

Martin Joyce

65 2013 Independent Director

Nancy Miller-rich

61 2020 Independent Director

Gary Phillips

54 2009 Independent Director

Jesse Treu

73 2013 Independent Director

Neal Walker

50 2013 Independent Director

Scott Solomon

IR Contact Officer

Biographies

Name Description

Richard Douglas

Dr. Richard H. Douglas Ph.D. serves as Independent Chairman of the Board of the Company. Dr. Douglas has served on our Board of Directors since September 2016. Dr. Douglas is the former Senior Vice President, Corporate Development of Genzyme Corporation. Since 2011, Dr. Douglas has been an independent consultant and advisor at Red Sky Partners LLC. From 1989 to 2011, he led Genzyme Corporation’s Corporate Development team, and was involved in numerous acquisitions, licenses, financings, joint ventures, and strategic alliances. From 1982 until its merger with Genzyme Corporation in 1989 (now Sanofi Genzyme), Dr. Douglas served in science and corporate development capacities at Integrated Genetics. Currently, Dr. Douglas is on the Board of Directors of Novavax, Inc., a publicly-traded clinical-stage vaccine company, and MaxCyte, Inc., a publically traded biotechnology company. Dr. Douglas also serves on the University of Michigan Technology Transfer National Advisory Board. Dr. Douglas received a B.S. in chemistry from the University of Michigan and a Ph.D. in biochemistry from the University of California, Berkeley, and he was a postdoctoral fellow in Leroy Hood’s laboratory at the California Institute of Technology. Dr. Douglas’ extensive knowledge of our business, experience as a board member of a publicly-traded biotechnology company, substantial scientific background, and expertise in developing, financing and providing strong executive leadership within the pharmaceutical industry contributed to our conclusion that he should serve as a director of our company.

Todd Brady

Dr. Todd C. Brady M.D. Ph.D. serves as President, Chief Executive Officer, Director of the Company. Dr. Brady has served as our President and Chief Executive Officer since January of 2012 and as a member of our Board of Directors since 2005. Prior to Aldeyra, Dr. Brady served as Entrepreneur in Residence at Domain Associates, LLC, a leading healthcare venture capital firm, where he was a Principal from 2004 to 2013. Dr. Brady currently serves on the Board of Directors of Evoke Pharma, Inc. and Spring Bank Pharmaceuticals, Inc., both of which are publicly traded healthcare companies. Dr. Brady holds a Ph.D. in pathology from Duke University Graduate School, a M.D. from Duke University Medical School, and an A.B. from Dartmouth College in Philosophy and Psychology. Dr. Brady’s extensive knowledge of our business, as well as his years of experience in the biotechnology industry, including executive leadership in several biotechnology companies, contributed to our conclusion that he should serve as a director of our company.

Joshua Reed

Mr. Joshua Reed serves as Chief Financial Officer of the Company. Mr. Reed has more than 20 years of financial operations, strategy, and investment banking experience. Prior to joining Aldeyra, from June 2016 to July 2018, Mr. Reed served as Vice President and Head of Finance for Bristol-Myers Squibb’s (BMS) United States and Puerto Rico operations, a $12 billion business unit from September 2013 to June 2016, Mr. Reed served as Executive Director, Corporate Financial Analysis for BMS Prior to that, Mr. Reed held roles of increasing responsibility at BMS, including positions in financial planning and analysis, supply chain finance, operations finance, and mergers and acquisitions. Prior to that, Mr. Reed was the Vice President, Strategic Business Development at JPMorgan Chase, and held investment banking positions at Credit Suisse First Boston, where he focused on mergers and acquisitions. Mr. Reed received a B.S. in Finance from Rutgers University and an M.B.A. with concentrations in Finance and Corporate Strategy from the University of Michigan’s Ross School of Business.

James Gow

Mr. James A. Gow M.D. serves as Senior Vice President - Clinical Development of the Company. Dr. Gow brings 20 years of leadership experience in clinical development and medical affairs at multinational ophthalmic companies. Prior to joining Aldeyra, from July 2019 to November 2019, Dr. Gow served as Vice President, Global Development Lead for lifitegrast (Xiidra®) on global clinical development projects at Novartis AG. Dr. Gow has also served in similar roles at Shire Pharmaceuticals Inc. from January 2018 to January 2019 and at Takeda Pharmaceutical Company Ltd. from January 2019 to June 2019 following Takeda’s acquisition of Shire in January 2019. During his career, Dr. Gow has held leadership positions of increasing responsibility at ISTA Pharmaceuticals, Inc. (acquired by Bausch and Lomb, Inc.), Bausch and Lomb, Inc. (acquired by Valeant Pharmaceuticals International, Inc., now Bausch Health Companies Inc.), Alcon Research, Ltd. from 2013 to 2016, and Inotek Pharmaceuticals Corporation (merged with Rocket Pharmaceuticals, Inc.) from 2016 to 2017. Dr. Gow received his B.Sc. major in zoology, B.Sc. (Med.), and M.D. from the University of Manitoba.

Stephen Machatha

Dr. Stephen Machatha Ph. D. serves as Senior Vice President, Technical Operations of the Company. Dr. Machatha joined Aldeyra in 2016 as Vice President of Chemistry Manufacturing and Controls. Prior to joining Aldeyra, from January 2014 to December 2015, Dr. Machatha was Director of Chemistry Manufacturing and Controls and Drug Product Development for Synageva Biopharmaceuticals, a biotechnology company acquired by Alexion Pharmaceuticals. Dr. Machatha led the Chemistry Manufacturing and Controls teams involved in the development and regulatory filing of KANUMATM (sebelipase alfa). Prior to his work at Synageva, Dr. Machatha held scientific and product development roles of increasing responsibilities at Cubist Pharmaceuticals (Acquired by Merck & Co.) and CyDex Pharmaceuticals (Acquired by Ligand Pharmaceuticals). Dr. Machatha attended the University of Arizona, where he received a Ph.D. in Pharmaceutical Sciences, an M.A. in Chemistry, and a B.Sc. in Chemistry.

David McMullin

Mr. David McMullin serves as Chief Commercial Officer of the Company. Mr. McMullin joined Aldeyra in 2018 as SVP Corporate Development and Strategy. Mr. McMullin has more than 20 years of biopharmaceutical industry experience, focused on commercialization, business development, and strategic planning operations. Since September 2017, Mr. McMullin has been an advisor on business development to nference, an artificial intelligence start-up synthesizing biomedical knowledge to deliver cutting-edge insights. Mr. McMullin was an executive at Shire plc from 2015 to 2017, as Group Vice President and Head of US Internal Medicine, a $1.4 billion commercial business, from March 2016 until May 2017, and running global commercial operations as VP and Head of Global Commercial Center of Excellence from March 2015 until March 2016. Mr. McMullin was a member of Shire’s In-Line Committee, the executive governing body responsible for commercial performance and execution worldwide, from March 2015 until March 2016. Prior to his work at Shire, Mr. McMullin was VP and Global Head of Supply Chain Operations and Strategy at Novartis Vaccines and Diagnostics from September 2010 until March 2015. Mr. McMullin led an operational turn-around of the supply chain, culminating with the successful acquisition of the business by GlaxoSmithKline plc and CSL Limited in 2015. Mr. McMullin held corporate, sales, marketing and operational roles of increasing responsibility at Novartis from 2003 until 2015, and was the Assistant to the Chairman and CEO of Novartis AG from 2003 until 2005. Before joining Novartis, Mr. McMullin worked at Charles River Associates, Inc. as a business strategy consultant. Mr. McMullin was awarded an M.B.A. with Baker Scholar distinction from Harvard Business School in 2003, and received both a B.A. in Food Science and a B.S. in Economics from Brigham Young University in 1999.

Ben Bronstein

Dr. Ben Bronstein M.D. serves as Independent Director of the Company. Dr. Bronstein is an independent consultant providing advisory services to companies in the life sciences industry. Prior to his consulting role, he was Executive Vice President, Clinical Development at Aclaris Therapeutics, Inc. He is a board-certified pathologist and dermatopathologist, with over 20 publications. Dr. Bronstein began his professional career on the staff of the Massachusetts General Hospital and on the faculty of Harvard Medical School. He has spent the past 29 years in entrepreneurial and management roles in life science companies and venture capital firms. Dr. Bronstein has founded or held senior management positions at several venture-backed life science companies including: Neuron Systems, Inc. (CEO), the predecessor company to Aldeyra Therapeutics, Inc.; BioSurface Technology, Inc., a regenerative medicine company; Peptimmune, Inc., an immunotherapeutics company (a spinout from Harvard and MIT); and Vidus Ocular, Inc., a Yale University spinout developing an implantable device for the treatment of glaucoma. Dr. Bronstein has served as Chief Medical Officer of Stealth BioTherapeutics, Inc., as a Visiting Scholar at the Wyss Institute of Biologically Inspired Engineering at Harvard Medical School and as a founder and Senior Vice President of Access BridgeGap Ventures, the life science investment unit of Access Industries, Inc. Dr. Bronstein serves on the boards of directors of several privately held life science companies. He is also a member of the Scientific Advisory Committee of the Daedalus Fund of Weill Cornell Medicine from which he resigned (retired) effective January 2020. Dr. Bronstein received his M.D. and M.B.A. from Boston University. Dr. Bronstein’s extensive knowledge of our business and history, experience as a board member of biotechnology companies and expertise in developing, financing and providing strong executive leadership to numerous biopharmaceutical companies contributed to our conclusion that he

Martin Joyce

Mr. Martin J. Joyce serves as Independent Director of the Company. Mr. Joyce’s professional background includes leadership roles in public and private, medical device, biotechnology and pharmaceutical companies from start-up stage to over $500 million in annual revenue. He has experience in public equity financings, business development, SEC reporting, strategic planning, mergers, acquisitions, investor relations and biotechnology operations. Since 2012, Mr. Joyce has served as a consultant to the life science industry assisting biotechnology and pharmaceutical companies in strategic planning, fund raising and operations. From March 2011 to July 2012, Mr. Joyce was Chief Financial Officer at Lucid Inc., an early stage skin cancer diagnostic company. Previously, Mr. Joyce served as Executive Vice President and Chief Financial Officer of BioSphere Medical from January 2006 through September 2010. He served as BioSphere’s Chief Financial Officer and Vice President from September 2004 to January 2006. From January 2001 to September 2004, Mr. Joyce served as Managing Partner of Stratex Group LLC, a provider of biopharmaceutical executive services to early-stage companies and venture investors. From 1996 to January 2001, Mr. Joyce was North American Chief Financial Officer for Serono Inc. a biotechnology company. From April 1987 to 1996, Mr. Joyce held a variety of senior level positions within Serono in finance, sales, marketing and manufacturing. Mr. Joyce was previously employed at Millipore Corporation, a high technology bioscience company. Mr. Joyce received a B.S. in finance from Northeastern University and a M.B.A. from Suffolk University, Boston, Massachusetts. Mr. Joyce’s extensive knowledge of our business and history, experience in multiple publicly-traded and privately-held companies, and expertise in developing, financing and providing strong executive leadership to numerous biopharmaceutical companies contributed to our conclusion that he should serve as a director of our company.

Nancy Miller-rich

Ms. Nancy Miller-rich serves as Independent Director of the Company. Ms. Miller-Rich has been a member of our board of directors since January 2020. She is Chief Executive of Miller-Rich Associates, a pharmaceutical industry consultancy she founded in 2017. Previously, she served as Senior Vice-President, Global Human Health Business Development & Licensing, Strategy and Commercial Support at Merck Pharmaceuticals. At Merck, Ms. Miller-Rich had direct P&L involvement in the $38 billion pharmaceutical division and closed approximately 300 deals producing $10 billion of value creation. Before that she worked for Schering-Plough Corporation, where she was Senior Vice President, Global Human Health Business Development & Licensing, Strategy and Commercial Support from 2013 to 2017 and Group Vice President, Consumer Care Global New Ventures and Strategic Commercial Development from 2007 to 2013. Prior to joining Schering-Plough in 1990, Ms. Miller-Rich served in a variety of commercial and marketing roles at Sandoz Pharmaceuticals and Sterling Drug, Inc. She is a director of Intercept Pharmaceuticals, Inc. and previously served as a director of UDG Healthcare plc. Ms. Miller-Rich also serves as a board member of a number of private and not-for-profit entities. Ms. Miller-Rich received her B.S. in Business Administration, Marketing from Ithaca College in Ithaca, New York. Ms. Miller-Rich’s public company experience, strong background in areas such as licensing, joint ventures, and global commercial development, contributed to our conclusion that she should serve as a director of our company.

Gary Phillips

Dr. Gary M. Phillips M.D. serves as Independent Director of the Company. Dr. Phillips has served as President & CEO of OrphoMed, Inc. since March 2018 and has been a member of our Board of Directors since May 2009. He was Executive Vice President & Chief Strategy Officer at Mallinckrodt Pharmaceuticals plc from October 2013 to March 2018. Before joining our company, Dr. Phillips held the dual roles of president, U.S. surgical and pharmaceuticals and global head of pharmaceuticals at Bausch & Lomb. He has served as the head of global health at the World Economic Forum in Geneva. Previously, he was president of Reckitt Benckiser Pharmaceuticals, Inc. (now Indivior). He has also held executive roles at Merck KGaA, Novartis and Wyeth (now Pfizer). He was a healthcare strategy managing consultant at Towers Perrin (now Willis Towers Watson) and a medical officer with the United States Navy, from which he was honorably discharged as a lieutenant commander. Dr. Phillips was educated at the University of Pennsylvania, where he received an M.D. (Alpha Omega Alpha) from the School of Medicine, an MBA from the Wharton School, and B.A. (summa cum laude, Phi Beta Kappa) in biochemistry from the College of Arts and Sciences. He completed postgraduate medical education at Naval Medical Center San Diego and maintains an active medical license. Dr. Phillips’ extensive knowledge of our business and history, and his experience in pharmaceutical strategy at multiple multinational companies, contributed to our conclusion that he should serve as a director of our company.

Jesse Treu

Dr. Jesse I. Treu Ph.D. serves as Independent Director of the Company. Dr. Treu has served on our Board of Directors since June 2013. Dr. Treu was a founding partner of Domain Associates, L.L.C. and became Partner Emeritus in 2018. He has been a director of over 38 early-stage healthcare companies. Dr. Treu currently serves as a member of the board of directors of Sebacia, Inc. He has also served as a founder, president and chairman of numerous venture-stage companies. Prior to the formation of Domain Associates, Dr. Treu had twelve years of experience in the healthcare industry. He was Vice President of the predecessor organization to The Wilkerson Group and its venture capital arm, CW Ventures. While at CW Ventures, he served as President and CEO of Microsonics, Inc., a pioneer in computer image processing for cardiology. Previous to that, Dr. Treu led new product development and marketing planning for immunoassay and histopathology products at Technicon Instruments Corporation, which is now part of Siemens Medical Solutions Diagnostics. Dr. Treu began his career with General Electric Company in 1973, initially as a research scientist developing thin film optical sensors for immunoassay testing, and later serving on the corporate staff with responsibility for technology assessment and strategic planning. Dr. Treu received his B.S. in Physics from Rensselaer Polytechnic Institute and his M.A. and Ph.D. in physics from Princeton University. Dr. Treu's extensive knowledge of our business and history, experience as a board member of multiple publicly-traded and privately-held companies and expertise in developing and financing contributed to our conclusion that he should serve as a director of our company.

Neal Walker

Dr. Neal Walker serves as Independent Director of the Company. Dr. Walker has served on our Board of Directors since June 2013. Dr. Walker is the President, Chief Executive Officer, and a director at Aclaris Therapeutics, Inc., a publicly-traded dermatological drug development company. Dr. Walker is a board certified dermatologist and serial entrepreneur with over 18 years of experience in the biopharmaceutical industry. Prior to founding Aclaris Therapeutics, Inc. in 2012, he was co-founder, President and CEO of Vicept Therapeutics, Inc. (acquired by Allergan, Inc.) from 2009 to 2012. Dr. Walker has co-founded and led a number of life science companies: Octagon Research Solutions, Inc., a software and services provider to biopharmaceutical companies (acquired by Accenture plc); Trigenesis Therapeutics, Inc., a specialty dermatology company where he served as Chief Medical Officer (acquired by Dr. Reddy's Laboratories Ltd); Cutix Inc., a commercial dermatology company that markets PreSun®, a sunscreen brand acquired from Bristol-Myers Squibb Co. He began his pharmaceutical industry career at Johnson and Johnson, Inc. Dr. Walker currently is on the Board of Directors of Aclaris Therapeutics, Inc., Sebacia, Inc. and Follica, Inc. (Executive Chairman). Dr. Walker previously served on the Board of Directors for Octagon, a contract research organization. He is also on the Advisory Board of Flexible Medical Systems LLC, a privately held medical device company. Dr. Walker received his MBA from The Wharton School, University of Pennsylvania, his D.O. from Philadelphia College of Osteopathic Medicine and a B.A. in Biology from Lehigh University. Dr. Walker's experience as a founder of two private pharmaceutical firms, strong background in clinical and product development in dermatology and other fields, and substantial knowledge of the pharmaceutical industry contributed to our conclusion that he should serve as a director of our company.

Scott Solomon

Basic Compensation

Name Fiscal Year Total

Richard Douglas

169,675

Todd Brady

4,141,260

Joshua Reed

2,181,280

James Gow

--

Stephen Machatha

--

David McMullin

1,584,440

Ben Bronstein

135,515

Martin Joyce

144,556

Nancy Miller-rich

--

Gary Phillips

131,743

Jesse Treu

139,538

Neal Walker

124,204

Scott Solomon

--
As Of  31 Dec 2019